Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics ( SIX/NASDAQ: ADXN ) , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C.
| Ticker |
Sentiment |
Impact |
|
INDV
|
Neutral
|
7 %
|
|
ADXN
|
Neutral
|
52 %
|
